Results 21 to 30 of about 31,380 (219)

Photodermatosis secondary to hydroxyurea [PDF]

BMJ Case Reports, 2014
A middle aged Southeast-Asian man, recently diagnosed with chronic myeloid leukaemia (Philadelphia positive on FISH), was started on cytoreductive therapy with hydroxyurea due to high leucocyte count (130 000/µL). The patient had no history of using any other drugs simultaneously or in the recent/remote past. He developed a clearly defined erythematous
Uday, Yanamandra, Kamal Kant, Sahu, Pankaj, Malhotra, Subhash, Varma   +3 more
openaire   +2 more sources

Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a patient with sickle Cell Anemia

Clinical Medicine Insights: Oncology, 2012
We report a 41 year old male with sickle cell disease who developed a myelodysplastic syndrome and acute myeloid leukemia with complex karyotype involving chromosomes 5, 7 and 17 after 15 years of hydroxyurea treatment.
Walid Baz, Vesna Najfeld, Matthew Yotsuya, Jotica Talwar, Terenig Terjanian, Frank Forte   +5 more
doaj   +1 more source

Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, Brazil

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: Sickle cell anemia is a hemoglobinopathy caused by a mutation that results in the production of an abnormal hemoglobin molecule, hemoglobin S (Hb S).
Paulo Florentino Teixeira Neto, Romélia Pinheiro Gonçalves, Darcielle Bruna Dias Elias, Cleiton Pinheiro de Araújo, Hemerson Iury Ferreira Magalhães   +4 more
doaj   +1 more source

Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial

JMIR Research Protocols, 2021
BackgroundSickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization.
Hood, Anna M, Strong, Heather, Nwankwo, Cara, Johnson, Yolanda, Peugh, James, Mara, Constance A, Shook, Lisa M, Brinkman, William B, Real, Francis J, Klein, Melissa D, Hackworth, Rogelle, Badawy, Sherif M, Thompson, Alexis A, Raphael, Jean L, Yates, Amber M, Smith-Whitley, Kim, King, Allison A, Calhoun, Cecelia, Creary, Susan E, Piccone, Connie M, Hildenbrand, Aimee K, Reader, Steven K, Neumayr, Lynne, Meier, Emily R, Sobota, Amy E, Rana, Sohail, Britto, Maria, Saving, Kay L, Treadwell, Marsha, Quinn, Charles T, Ware, Russell E, Crosby, Lori E   +31 more
doaj   +1 more source

Differences in HRQOL among Children with SCD Who Received Hydroxyurea and Those Who Did Not: A Quantitative Comparison Study

Oman Medical Journal
Objectives: Hydroxyurea is been recommended for patients with sickle cell disease (SCD) as it reduces the complications from the disease by increasing the production of fetal hemoglobin.
Yusra Al Nasiri, Amal Al Sabahi, Karima Al Hanai, Mohammed Al Hanai, Shah Mohammed Wasifuddin, Nawal Al Mashayki, Mudhar Al Adawi, Kamla Al Nassri, Salah Al Awaidy   +8 more
doaj   +1 more source

Iron Chelation Reduces DNA Damage in Sickle Cell Anemia

Clinical and Applied Thrombosis/Hemostasis, 2021
Sickle cell anemia (SCA) is a blood condition that causes severe pain. One of the therapeutic agents used for the treatment of SCA is hydroxyurea, which reduces the episodes of pain but causes DNA damage to white blood cells. The aim of this study was to
Rawan S. Al-Khateeb, Hanan S. Althagafy, Mohammad Zaki ElAssouli, Dunya A. Nori, Mohammed AlFattani, Salwa A. Al-Najjar, Turki Al Amri, Anwar M. Hashem, Steve Harakeh, Nawal Helmi   +9 more
doaj   +1 more source

Consensus Standards and Recommendations for Developmental and Cognitive Surveillance, Screening, and Evaluation in Sickle Cell Disease: Executive Summary From the National Alliance of Sickle Cell Centers Neurocognitive Workgroup

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neurodevelopmental and neurocognitive difficulties are prevalent among individuals with sickle cell disease and warrant prompt identification and support. This Special Report provides an executive summary of standards and recommendations for surveillance, screening, and evaluation for development and cognition across the lifespan developed by ...
Alyssa M. Schlenz, Donna Murdaugh, Andrew M. Heitzer, Jennifer N. Longoria, Wendy Santos‐Modesitt, Arianna Martin, Judy Cavazos, Jeff Schatz, Catherine R. Hoyt, Alison King, Eboni I. Lance, Steven Hardy, Marsha Treadwell   +12 more
wiley   +1 more source

Widespread Natural Occurrence of Hydroxyurea in Animals. [PDF]

PLoS ONE, 2015
Here we report the widespread natural occurrence of a known antibiotic and antineoplastic compound, hydroxyurea in animals from many taxonomic groups.
David I Fraser, Kyle T Liu, Bryan J Reid, Emily Hawkins, Andrew Sevier, Michelle Pyle, Jacob W Robinson, Pierre H R Ouellette, James S Ballantyne   +8 more
doaj   +1 more source

Improvement of Sickle Cell Disease Care Mitigates the Healthcare Utilization Induced by Increased Prevalence: Experience of a Tertiary Pediatric Center

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure We aimed to assess
Maude Cigna, Alexia Muresan, Estelle Lecluze, Karine Leduc, Nathalie Fournier, Maria Tamer, Jean‐François Delisle, Jeremi Charbonneau, Annie Viau, Jessica Darilus, Marie‐Joëlle Doré‐Bergeron, Valérie Arsenault, Evelyne Doyon‐Trottier, Stéphanie Forte, Nancy Robitaille, Yves Pastore, Thomas Pincez   +16 more
wiley   +1 more source

Secretory Phospholipase A2 in Patients With Sickle Cell Disease Hospitalized for Vaso‐Occlusive Pain Episodes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Secretory phospholipase A2 (sPLA2) is an inflammatory mediator linked to acute chest syndrome (ACS) in sickle cell disease (SCD), a serious complication that can develop during an acute vaso‐occlusive pain episode (VOE). Plasma sPLA2 levels have been proposed as a potential biomarker for predicting ACS onset.
Rawan Korman, Maria Yasmine, Dunia Hatabah, Noor Alzraikat, Frank Harris, Lou Ann Brown, Satheesh Chonat, Nitya Bakshi, Chris A. Rees, Carlton Dampier, Claudia R. Morris   +10 more
wiley   +1 more source